Pneumococcal conjugate vaccines (PCVs) have been extraordinarily effective in directly reducing the risk of invasive pneumococcal disease, meningitis, pneumonia, and otitis media in children, and have also induced herd protection.^1–4 The available PCVs are either ten valent (PCV10) or 13 valent (PCV13), are made by two multinational companies, are given to infants and toddlers in three to four doses, and are distributed least in Asia, despite that being the continent where more children are born than any other.

中文翻译：

---

儿科肺炎球菌结合疫苗的未来

肺炎球菌结合疫苗（PCV）在直接降低儿童侵袭性肺炎球菌疾病，脑膜炎，肺炎和中耳炎的风险方面非常有效，并且还诱导了牛群保护。^1-4可用的PCV是10价（PCV10）或13价（PCV13），由两家跨国公司生产，以3至4剂的剂量提供给婴幼儿，并且在亚洲的分布最少，尽管这是出生儿童最多的非洲大陆。